File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Efficacy and safety of single-agent sunitinib in treating advanced hepatocelluar carcinoma patients after sorafenib failure: a prospective, open-label, phase II study (Abstract)

TitleEfficacy and safety of single-agent sunitinib in treating advanced hepatocelluar carcinoma patients after sorafenib failure: a prospective, open-label, phase II study (Abstract)
Authors
Issue Date2011
Citation
ESMO 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22-25 June 2011. Annals of Oncology. In Annals of Oncology, v. 22 n. Suppl 5 How to Cite?
AbstractBackground: This is an open label and single arm phase II study to assess the efficacy and tolerability of sunitinib for the treatment of sorafenib-refractory advanced hepatocellular carcinoma (HCC) patients. Methods: Between October, 2008 and October, 2010, eligible patients with advanced HCC and documented disease progression after sorafenib treatment received sunitinib 37.5 mg continuously at Queen Mary Hospital, Hong Kong. Response assessment was performed after every 8 weeks. The primary endpoint was time-to-progression (TTP) and the secondary endpoints were tumor response rate (RR), overall survival (OS) and safety. Results: At the time of analysis, 38 patients were recruited in the trial. The median age was 56 years (range, 27-80) and all patients were in ECOG Performance Status 0-1. Ninety-five percent of patients were chronic hepatitis B carriers with underlying Child- Pugh A and B cirrhosis in 70% and 30% of the enrolled patients, respectively. Ten (25%) patients had tumor vascular invasion and 32 (80%) patients had extra-hepatic metastasis. Among 35 evaluable patients, RR was 6% with 2 patients achieved partial response and another 12 (34%) patients achieved stable disease. Overall, 40% of patients derived clinical benefits from sunitinib treatment for at least 8 weeks. The median TTP was 2.9 months (0.5-15) and OS was 5.2 months (1-22.5). Malaise (60%), neutropenia (45%) and diarrhea (36%) were the most commonly encountered adverse events, with nearly 30% of patients experienced grade 3 or 4 toxicity. No treatmentrelated death was reported. Conclusions: Sunitinib has substantial anti-tumour activity with manageable toxicity profile in treating sorafenib-refractory advanced HCC population. These data may imply sunitinib inhibits signaling pathways involved in sorafenib resistance and support the hypothesis of sequential use of antiangiogenic tyrosine kinase inhibitors in treating advanced HCC patients
DescriptionP-0216
Persistent Identifierhttp://hdl.handle.net/10722/137895
ISSN
2014 Impact Factor: 7.040

 

DC FieldValueLanguage
dc.contributor.authorYau, TCCen_US
dc.contributor.authorLeung, RCYen_US
dc.contributor.authorWong, Hen_US
dc.contributor.authorChiu, Jen_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorPang, RWCen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2011-08-26T14:36:33Z-
dc.date.available2011-08-26T14:36:33Z-
dc.date.issued2011en_US
dc.identifier.citationESMO 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22-25 June 2011. Annals of Oncology. In Annals of Oncology, v. 22 n. Suppl 5en_US
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/137895-
dc.descriptionP-0216-
dc.description.abstractBackground: This is an open label and single arm phase II study to assess the efficacy and tolerability of sunitinib for the treatment of sorafenib-refractory advanced hepatocellular carcinoma (HCC) patients. Methods: Between October, 2008 and October, 2010, eligible patients with advanced HCC and documented disease progression after sorafenib treatment received sunitinib 37.5 mg continuously at Queen Mary Hospital, Hong Kong. Response assessment was performed after every 8 weeks. The primary endpoint was time-to-progression (TTP) and the secondary endpoints were tumor response rate (RR), overall survival (OS) and safety. Results: At the time of analysis, 38 patients were recruited in the trial. The median age was 56 years (range, 27-80) and all patients were in ECOG Performance Status 0-1. Ninety-five percent of patients were chronic hepatitis B carriers with underlying Child- Pugh A and B cirrhosis in 70% and 30% of the enrolled patients, respectively. Ten (25%) patients had tumor vascular invasion and 32 (80%) patients had extra-hepatic metastasis. Among 35 evaluable patients, RR was 6% with 2 patients achieved partial response and another 12 (34%) patients achieved stable disease. Overall, 40% of patients derived clinical benefits from sunitinib treatment for at least 8 weeks. The median TTP was 2.9 months (0.5-15) and OS was 5.2 months (1-22.5). Malaise (60%), neutropenia (45%) and diarrhea (36%) were the most commonly encountered adverse events, with nearly 30% of patients experienced grade 3 or 4 toxicity. No treatmentrelated death was reported. Conclusions: Sunitinib has substantial anti-tumour activity with manageable toxicity profile in treating sorafenib-refractory advanced HCC population. These data may imply sunitinib inhibits signaling pathways involved in sorafenib resistance and support the hypothesis of sequential use of antiangiogenic tyrosine kinase inhibitors in treating advanced HCC patients-
dc.languageengen_US
dc.relation.ispartofESMO 13th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 22-25 June 2011. Annals of Oncologyen_US
dc.titleEfficacy and safety of single-agent sunitinib in treating advanced hepatocelluar carcinoma patients after sorafenib failure: a prospective, open-label, phase II study (Abstract)en_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailPang, RWC: robertap@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityPang, RWC=rp00274en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.doi10.1093/annonc/mdr287-
dc.identifier.hkuros189740en_US
dc.identifier.volume22en_US
dc.identifier.issueSuppl 5en_US
dc.customcontrol.immutableyiu 140314-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats